TCM Biotech International Corp. (TPE:4169)
Taiwan · Delayed Price · Currency is TWD 121.50
+0.50 (0.41%)
Nov 13, 2026, 1:30 PM CST
TCM Biotech International Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 715.3 | 685.49 | 666.53 | 969.62 | 802.42 | 702.05 | |
Revenue Growth | 4.82% | 2.84% | -31.26% | 20.84% | 14.30% | -4.75% |
Cost of Revenue | 387.1 | 368.5 | 339.22 | 489.45 | 353.93 | 343.33 |
Gross Profit | 328.2 | 316.99 | 327.31 | 480.17 | 448.49 | 358.72 |
Selling, General & Admin | 254.01 | 210.57 | 224.09 | 380.38 | 340.9 | 276.14 |
Research & Development | 115.39 | 88.42 | 93.22 | 77.46 | 81.8 | 80.45 |
Operating Expenses | 369.38 | 298.34 | 316.61 | 457.84 | 423.19 | 356.59 |
Operating Income | -41.18 | 18.65 | 10.7 | 22.33 | 25.3 | 2.13 |
Interest Expense | -0.57 | -0.86 | -1.61 | -2.77 | -2.39 | -1.97 |
Interest & Investment Income | 9.69 | 5.69 | 4.69 | 1.55 | 0.14 | 0.04 |
Currency Exchange Gain (Loss) | - | - | - | - | 0.01 | 0.44 |
Other Non Operating Income (Expenses) | 3.05 | -0.51 | 11.24 | 0.93 | 0.07 | 0.71 |
EBT Excluding Unusual Items | -29.01 | 22.97 | 25.02 | 22.03 | 23.13 | 1.35 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.91 |
Asset Writedown | -0.67 | -0.67 | - | - | - | - |
Pretax Income | -29.68 | 22.3 | 25.02 | 22.03 | 23.13 | 2.26 |
Income Tax Expense | 0.39 | 3.13 | 4.01 | 3.46 | 4.86 | 0.38 |
Net Income | -29.56 | 19.17 | 21.01 | 18.57 | 18.27 | 1.87 |
Net Income to Common | -29.56 | 19.17 | 21.01 | 18.57 | 18.27 | 1.87 |
Net Income Growth | - | -8.76% | 13.11% | 1.69% | 875.17% | -92.67% |
Shares Outstanding (Basic) | 61 | 59 | 59 | 53 | 49 | 49 |
Shares Outstanding (Diluted) | 61 | 59 | 59 | 53 | 49 | 49 |
Shares Change | 2.94% | -0.02% | 11.37% | 8.03% | 0.89% | 0.42% |
EPS (Basic) | -0.49 | 0.32 | 0.36 | 0.35 | 0.37 | 0.04 |
EPS (Diluted) | -0.49 | 0.32 | 0.36 | 0.35 | 0.37 | 0.04 |
EPS Growth | - | -10.06% | 1.66% | -5.41% | 861.49% | -92.66% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 8.3 | 34.65 | 159.42 | -41.51 | 48.46 | 11.19 |
Free Cash Flow Per Share | 0.14 | 0.59 | 2.70 | -0.78 | 0.99 | 0.23 |
Dividend Per Share | 0.360 | 0.360 | 0.350 | 0.285 | 0.033 | - |
Dividend Growth | 2.86% | 2.86% | 22.81% | 763.64% | -90.55% | - |
Gross Margin | 45.88% | 46.24% | 49.11% | 49.52% | 55.89% | 51.10% |
Operating Margin | -5.76% | 2.72% | 1.60% | 2.30% | 3.15% | 0.30% |
Profit Margin | -4.13% | 2.80% | 3.15% | 1.92% | 2.28% | 0.27% |
Free Cash Flow Margin | 1.16% | 5.05% | 23.92% | -4.28% | 6.04% | 1.59% |
EBITDA | -24.84 | 36.69 | 28.61 | 39.52 | 40.86 | 16.42 |
EBITDA Margin | -3.47% | 5.35% | 4.29% | 4.08% | 5.09% | 2.34% |
D&A For EBITDA | 16.34 | 18.03 | 17.92 | 17.19 | 15.56 | 14.29 |
EBIT | -41.18 | 18.65 | 10.7 | 22.33 | 25.3 | 2.13 |
EBIT Margin | -5.76% | 2.72% | 1.60% | 2.30% | 3.15% | 0.30% |
Effective Tax Rate | - | 14.03% | 16.02% | 15.70% | 21.02% | 17.01% |